NOVEL SACUBITRIL CALCIUM/VALSARTAN CO-CRYSTAL AND CO-AMORPHOUS FORM

摘要

The objective of the present invention is to provide a novel sacubitril calcium/valsartan co-crystal and co-amorphous form which overcomes the low stability, water solubility, and ease of formulation of sacubitril/valsartan sodium 2.5 hydrate, which is currently used as a therapeutic agent for chronic heart failure.